Specialty / Expertise

Breast cancer

Research Interests

Current Research Projects

Research Staff

Training

Dr. Ellis received her MD from the University of Washington, Seattle, WA. She completed her Internal Medicine Residency at the University of Washington, Seattle, WA. She was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.

Selected Publications:

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunwald LK, Mankoff DA. Serial 2-[18F] flouro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007 105(1):87-94.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra P, Peterson LM, Schubert E, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment. J Clin Oncol 2006 24(18):2793-2799.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE Schubert EK, Mankoff DA. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 2005 103(4):680-688.

Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004 183(2):479-486.

Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004 27(4):407-410.

McCune JS, Hatfield AJ, Blackburn AR, Leith PO, Livingston RB, Ellis GK. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004 12(6):454-462.